Expert Review of Anti-infective Therapy最新文献

The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis. 无创唑抗真菌治疗外阴阴道念珠菌病的未来。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-13 DOI: 10.1080/14787210.2025.2516554

Guillermo Quindós, Cristina Marcos-Arias, Katherine Miranda-Cadena, Elena Sevillano, Nerea Jauregizar, José Schneider, Elena Eraso

{"title":"The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis.","authors":"Guillermo Quindós, Cristina Marcos-Arias, Katherine Miranda-Cadena, Elena Sevillano, Nerea Jauregizar, José Schneider, Elena Eraso","doi":"10.1080/14787210.2025.2516554","DOIUrl":"10.1080/14787210.2025.2516554","url":null,"abstract":"Introduction: High worldwide prevalence and significant morbidity of vulvovaginal candidiasis (VVC) requires better therapeutic approaches to improve quality of life of affected women. Although treatment of acute episodes is often straightforward, complicated and recurrent vulvovaginal candidiasis (RVVC) presents medical challenges.Area covered: This review focuses on therapy of VVC particularly by topical antifungals , especially imidazoles, compared to oral treatment with fluconazole, itraconazole, ibrexafungerp, or oteseconazole. Candidiasis by non-Candida albicans, VVC in pregnant women and RVVC are complex challenges . Current treatment, alternatives, and roles played by topical azoles in VVC are highlighted.Expert opinion: VVC requires personalized treatment considering whether the woman is pregnant or not, concomitant treatments, clinical presentations (acute or recurrent) and the Candida species involved. Although therapeutic tools are increasing, the usefulness of topical drugs, such as clotrimazole and miconazole, is very relevant. In addition, we it is also necessary to expand the therapeutic tools with new antifungals and formulations, and repurposing current drugs against fluconazole-resistant species of Candida.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":4.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Invasive Candida in the abdomen: how to differentiate infection from colonization. 腹部侵袭性念珠菌：如何区分感染与定植。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-11 DOI: 10.1080/14787210.2025.2516553

Corentin Deckers, Isabel Montesinos, Pierre Emmanuel Plum, Matteo Bassetti, Patrick M Honoré

{"title":"Invasive Candida in the abdomen: how to differentiate infection from colonization.","authors":"Corentin Deckers, Isabel Montesinos, Pierre Emmanuel Plum, Matteo Bassetti, Patrick M Honoré","doi":"10.1080/14787210.2025.2516553","DOIUrl":"10.1080/14787210.2025.2516553","url":null,"abstract":"Introduction: Intra-abdominal candidiasis (IAC) is a serious complication in critically ill patients, particularly after abdominal surgery or trauma. Differentiating Candida colonization from invasive infection is crucial, as misdiagnosis can lead to inappropriate antifungal use, increased resistance, and worse outcomes. However, IAC remains underrecognized due to the limitations of conventional culture-based diagnostics. Relevant literature was identified through a non-systematic search of the PubMed database.Areas covered: This review highlights the challenges in diagnosing and managing IAC, focusing on the limitations of traditional culture methods and the potential of non-culture-based diagnostics. Biomarkers such as 1-3-β-D-glucan (BDG) and Candida albicans germ tube antibody (CAGTA), along with molecular assays, improve diagnostic accuracy but have varying sensitivity and specificity, requiring a multimodal approach. Management involves early diagnosis, source control, and targeted antifungal therapy. Current guidelines, largely based on candidemia, recommend echinocandins as first-line therapy, with fluconazole for stable patients and amphotericin B for resistant strains.Expert opinion: Despite advances, IAC-specific research is lacking, necessitating improved diagnostic tools and tailored therapies. There is a need for more targeted studies to refine diagnostic algorithms and therapeutic strategies. Future efforts should focus on developing rapid, high-sensitivity and specific diagnostic tools, optimizing antifungal stewardship, and individualizing treatment approaches.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":4.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using Lab-linked claims Data in the United States. 实体器官移植后巨细胞病毒患者从缬更昔洛韦治疗转向马里巴韦治疗的实际有效性和耐受性：使用美国实验室相关索赔数据的分析

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-06 DOI: 10.1080/14787210.2025.2517344

Krithika Rajagopalan, Michael Bullano, Daniele Gelone, Tien Bo, Vamshidhar Taduka, Safiuddin Shoeb Syed

{"title":"Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using Lab-linked claims Data in the United States.","authors":"Krithika Rajagopalan, Michael Bullano, Daniele Gelone, Tien Bo, Vamshidhar Taduka, Safiuddin Shoeb Syed","doi":"10.1080/14787210.2025.2517344","DOIUrl":"https://doi.org/10.1080/14787210.2025.2517344","url":null,"abstract":"Background: Antiviral (AV) treatment options (e.g. Valganciclovir, VGCV) for cytomegalovirus (CMV) infections present a challenging benefit-risk profile (e.g. bone-marrow suppression) and potentially increased resistance and refractoriness. Maribavir (MBV), a new AV treatment approved for refractory/resistant post-transplant CMV infections, demonstrated superior viral clearance in SOLSTICE trial.Research design and methods: A retrospective lab-linked claims analysis of solid organ transplant (SOT) patients on VGCV (≥900 mg BID) treatment who newly switched to MBV (i.e. index date) between 12/01/21-12/31/23. MBV treatment effectiveness (CMV viremia clearance/no treatment switch) and tolerability (e.g. leukopenia) during 3-months pre- and post-index were examined.Results: Of 1,247 post-SOT VGCV-treated patients, 81 switched to MBV; mean age was 55 years and 73% had kidney transplant. Among 33 with follow-up labs, 88% (n = 29) achieved viral clearance. Of the remaining 48 without follow-up labs, 60.4% (n = 29) did not switch to other AV treatments. The combined treatment effectiveness was 71.6%. Tolerability issues decreased after MBV initiation: with leukopenia, neutropenia, nausea, and diarrhea decreasing by 14.3%, 3.57%, 14.3%, and 17.86%, respectively.Conclusion: MBV-treated patients had 10-15% lower tolerability issues; over 7 in 10 demonstrated treatment effectiveness in this real-world analysis. MBV's favorable benefit-risk profile makes it a potentially valuable addition to the CMV treatment armamentarium.Clinical trial registration: www.clinicaltrials.gov identifier is NCT02931539.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phage therapy in patients with urinary tract infections: a systematic review. 噬菌体治疗尿路感染：系统综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-04 DOI: 10.1080/14787210.2025.2513459

Romaric Larcher, Aurélien Dinh, Boris Monnin, Paul Laffont-Lozes, Paul Loubet, Jean-Philippe Lavigne, Franck Bruyere, Albert Sotto

{"title":"Phage therapy in patients with urinary tract infections: a systematic review.","authors":"Romaric Larcher, Aurélien Dinh, Boris Monnin, Paul Laffont-Lozes, Paul Loubet, Jean-Philippe Lavigne, Franck Bruyere, Albert Sotto","doi":"10.1080/14787210.2025.2513459","DOIUrl":"10.1080/14787210.2025.2513459","url":null,"abstract":"Introduction: Urinary tract infections (UTIs) caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are challenging to treat. This systematic review evaluates bacteriophage therapy.Research design and methods: A comprehensive search was conducted in PubMed, Embase, Web of Science, and Cochrane databases. Studies reporting bacteriophage therapy in UTIs, with outcomes related to safety and efficacy, were included. Studies unrelated to UTIs or lacking clear outcomes were excluded. Bias was assessed using RoB2 and JBI appraisal tools for series and case reports. Data were synthesized narratively due to study heterogeneity.Results: From 576 articles screened, 12 studies met the inclusion criteria, comprising 89 participants, many with MDR and XDR infections. Phage therapy was generally well-tolerated. Efficacy varied, with some studies showing complete infection resolution, particularly in high-risk patients, while others reported partial or no improvement. Phage therapy often served as the sole viable treatment for XDR infections, yielding positive results despite small sample sizes and data heterogeneity.Conclusions: Phage therapy shows promise as an alternative or adjunct to antibiotics for UTIs, especially those with limited treatment options, but uncertainties remain regarding dosing and administration. Further randomized trials are needed to confirm its efficacy and safety.Protocol registration: www.crd.york.ac.uk/prospero identifier isCRD42023431617.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":4.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surge of branded generics and antimicrobial resistance: analyzing the antibiotic market dynamics in Pakistan through the WHO essential medicines and AWaRe lens. 品牌仿制药激增和抗微生物药物耐药性：通过世卫组织基本药物和AWaRe镜头分析巴基斯坦抗生素市场动态。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-02 DOI: 10.1080/14787210.2025.2511958

Saad Abdullah, Zikria Saleem, Brian Godman, Furqan Khurshid Hashmi, Abdul Haseeb, Mahmood Basil A Al-Rawi, Muhammad Usman Qamar, Mike Sharland

{"title":"Surge of branded generics and antimicrobial resistance: analyzing the antibiotic market dynamics in Pakistan through the WHO essential medicines and AWaRe lens.","authors":"Saad Abdullah, Zikria Saleem, Brian Godman, Furqan Khurshid Hashmi, Abdul Haseeb, Mahmood Basil A Al-Rawi, Muhammad Usman Qamar, Mike Sharland","doi":"10.1080/14787210.2025.2511958","DOIUrl":"10.1080/14787210.2025.2511958","url":null,"abstract":"Background: Access to safe and effective antibiotics is crucial in low- and middle-income countries (LMICs) coupled with reducing their overuse to reduce antimicrobial resistance (AMR). We sought to systematically analyze the extent of branded generic antibiotics in Pakistan, particularly Watch antibiotics, given concerns with AMR in Pakistan.Research design and methods: Data on registered antibiotics was collected from the Drug Regulatory Authority of Pakistan (DRAP) and the Pharmaguides. Two hundred and fifty-seven antibiotics were analyzed using the AWaRe classification.Results: Of these, 99 were registered in Pakistan including 91 single entities and 8 combinations, with 6,025 brands and 14,076 presentations. Distribution across AWaRe categories included Access - 37, Watch - 56, and Reserve - 6. Cephalosporins (2186 brands, 6447 presentations) and Quinolones (1333 brands, 2586 presentations) are the most prevalent, with ciprofloxacin (393 brands, 1158 presentations) leading in brand and presentation counts. Six antibiotics from the WHO Essential Medicines List lacked registered brands in Pakistan, while many available antibiotics were not included in the WHO framework.Conclusion: Extensive availability of branded generic antibiotics, particularly Watch antibiotics, in Pakistan poses a serious risk, exacerbated by the current misuse of antibiotics. Improving regulatory frameworks and strengthening stewardship are critical to reducing AMR in Pakistan along with addressing uncontrolled registration by DRAP.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":4.2,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lessons from the past: what does the future of clinical management of infection after solid organ transplantation look like? 过去的教训：实体器官移植后感染的临床管理的未来是什么样的？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-02 DOI: 10.1080/14787210.2025.2513461

Mario Fernández-Ruiz, José María Aguado

{"title":"Lessons from the past: what does the future of clinical management of infection after solid organ transplantation look like?","authors":"Mario Fernández-Ruiz, José María Aguado","doi":"10.1080/14787210.2025.2513461","DOIUrl":"10.1080/14787210.2025.2513461","url":null,"abstract":"Introduction: Infection continues to be one of the most common complications after solid organ transplantation (SOT). Past years have witnessed major advances in the diagnosis, prevention and treatment of post-transplant infection. Nevertheless, controversial issues and unmet needs remain.Areas covered: We review recent contributions to the use of organs from hepatitis C or human immunodeficiency virus-positive donors or those with positive cultures for multidrug resistant organisms (MDROs), diagnostic next-generation sequencing, selective digestive decolonization (SDD), immune monitoring strategies for individualized risk assessment, vaccines and prophylactic monoclonal antibodies, and the prospects of adoptive T-cell immunotherapy and chimeric antigen receptor cell products. Based on these lessons, plausible future developments in the prevention and management of post-transplant infection are proposed.Expert commentary: We expect that current barriers for the acceptance of increased infection risk donors will be overcome, and that the arrival of new antibiotics will allow the use of organs from donors colonized or infected by MDROs. 'Pathogen-agnostic' high-throughput diagnostic approaches will progressively replace conventional microbiology methods. Prophylaxis will be individualized by means of peri-transplant SDD, a repertoire of immune biomarkers (including the changes in human virome), and passive pre-exposure immunization. Finally, advanced cellular therapies will become the standard care of SOT recipients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-19"},"PeriodicalIF":4.2,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges. 2025年COVID-19抗病毒药物的开发：未满足的需求和未来的挑战

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-04 DOI: 10.1080/14787210.2025.2473044

Daniele Focosi, David J Sullivan, Massimo Franchini

引用次数: 0

Treatment of chronic hepatitis C infection: strategies to address poor therapy adherence. 慢性丙型肝炎感染的治疗：解决治疗依从性差的策略

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-30 DOI: 10.1080/14787210.2025.2486353

Robert Flisiak, Piotr Rzymski, Marta Flisiak-Jackiewicz, Michał Brzdęk, Dorota Zarębska-Michaluk

{"title":"Treatment of chronic hepatitis C infection: strategies to address poor therapy adherence.","authors":"Robert Flisiak, Piotr Rzymski, Marta Flisiak-Jackiewicz, Michał Brzdęk, Dorota Zarębska-Michaluk","doi":"10.1080/14787210.2025.2486353","DOIUrl":"10.1080/14787210.2025.2486353","url":null,"abstract":"Introduction: Non-adherence to any therapy may be related to skipping drug doses, discontinuation of therapy, or loss of follow-up. It leads to the ineffectiveness of treatment, which is associated with obvious individual health losses, significant social and financial costs, and, in the case of infectious diseases, epidemiological consequences resulting from the possibility of further spread of infection.Areas covered: This review article analyses the causes and effects of non-adherence to treatment in patients infected with the hepatitis C virus (HCV). It also presents strategies to reduce the risk of non-adherence, which can be implemented by simplifying the treatment process, improving the flow of information between the doctor and the patient, as well as improving patients' knowledge about hepatitis C infection, and facilitating the understanding of the risks associated with non-adherence.Expert opinion: Since the treatment of HCV infections is highly effective in almost all patients who complete medication, no new drugs are to be expected in the coming years. Therefore, the primary attention in the global elimination of HCV will be focused on screening programs, improving the availability of drugs, and reducing the risk of non-adherence.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"379-387"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standard dose could be better! A multicenter study of tigecycline in patients with liver failure. 标准剂量可能更好！替加环素在肝功能衰竭患者中的多中心研究。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-02-26 DOI: 10.1080/14787210.2025.2472346

Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin

{"title":"Standard dose could be better! A multicenter study of tigecycline in patients with liver failure.","authors":"Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin","doi":"10.1080/14787210.2025.2472346","DOIUrl":"10.1080/14787210.2025.2472346","url":null,"abstract":"Background: High-dose (HD) tigecycline is often required for severe multidrug-resistant gram-negative infections in liver failure patients, despite package recommendations to halve the dose for those with severe liver impairment. This study evaluated the efficacy and safety of different tigecycline doses in this population.Research design and methods: A retrospective cohort of 192 patients with Child-Pugh grade C liver failure was divided into label-dose (LD), standard-dose (SD), and HD groups. Primary and secondary outcomes included microbial eradication, mortality, and adverse effects.Results: The SD group achieved higher microbial eradication than LD, with comparable efficacy to HD but fewer adverse events, such as fibrinogen requirements. High-dose treatment increased mortality risk (Hazard Ratio: 1.85, p = 0.062). Optimal microbial eradication and minimized adverse effects occurred with the SD group at 7 days of treatment.Conclusions: Standard-dose tigecycline offers a balanced approach to microbial eradication and safety, making it preferable in liver failure patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"415-423"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of methicillin-resistant Staphylococcus aureus bloodstream infections: a comprehensive narrative review of available evidence focusing on current controversies and the challenges ahead. 耐甲氧西林金黄色葡萄球菌血流感染的管理：对现有证据的全面回顾，重点关注当前的争议和未来的挑战。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-10 DOI: 10.1080/14787210.2025.2487163

Alberto Enrico Maraolo, Milo Gatti, Luigi Principe, Andrea Marino, Giuseppe Pipitone, Gennaro De Pascale, Giancarlo Ceccarelli

{"title":"Management of methicillin-resistant Staphylococcus aureus bloodstream infections: a comprehensive narrative review of available evidence focusing on current controversies and the challenges ahead.","authors":"Alberto Enrico Maraolo, Milo Gatti, Luigi Principe, Andrea Marino, Giuseppe Pipitone, Gennaro De Pascale, Giancarlo Ceccarelli","doi":"10.1080/14787210.2025.2487163","DOIUrl":"10.1080/14787210.2025.2487163","url":null,"abstract":"Introduction: Bloodstream infections (BSIs) caused by Staphylococcus aureus are common worldwide, representing one of the most relevant issues in clinical infectious diseases practice. In particular, BSIs by methicillin-resistant S. aureus (MRSA-BSI) are still today a challenge since mortality burden remains elevated although decades of research.Areas covered: The following topics regarding MRSA-BSI were reviewed and discussed by resorting to best available evidence retrieved from PubMed/MEDLINE up to October 2024: i) epidemiology; ii) microbiology; iii) classification, with a focus on complicated and not complicated forms; iv) the structured approach to the patient; v) pharmacokinetics and pharmacodynamics of the main antimicrobial options; vi) controversies regarding the best therapeutic approach.Expert opinion: Despite ongoing efforts to better stratify and manage MRSA-BSI, there is no universally accepted classification system accurately distinguishing between uncomplicated/low risk and complicated/high risk forms. Biomarkers such as interleukin(IL)-10 hold promise in order to enable a more precise stratification, premise for an appropriate treatment plan. There is a theoretical rationale for implementing a combination therapy including a beta-lactam agent upfront, especially for patients considered at higher risk of unfavorable outcomes, but further data are necessary, and the same applies to newer adjuvants. Novel microbiological techniques may help in guiding antimicrobial duration.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"389-414"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0